The diagnosis of HPRT deficiency in the 21st century.
We have studied 36 patients with HPRT deficiency, 25 with Lesch-Nyhan syndrome and 11 with partial HPRT deficiency (grades 1 to 3). Patients diagnosed with HPRT deficiency have increased 50% since 2000. The most relevant recent advances have been made in molecular diagnosis. Nevertheless, enzyme determinations are still essential for the diagnosis of HPRT deficiency. Therapy for the neurological manifestations of HPRT deficiency has not advanced. Allopurinol remains the drug of choice to diminish uric acid overproduction, but the optimal allopurinol dose must be established in each patient to prevent xanthine or uric acid urolithiasis, a process aided by sequential determination of urinary oxypurines and uric acid.
Torres
R J
RJ
Division of Clinical Biochemistry, La Paz University Hospital, Madrid, Spain. rtorres.hulp@salud.madrid.org
Puig
J G
JG
D000293:Adolescent; D000493:Allopurinol / Q000627:therapeutic use; D002675:Child, Preschool; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000172:deficiency* / Q000235:genetics / Q000378:metabolism*; D007926:Lesch-Nyhan Syndrome / Q000175:diagnosis* / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism; D009154:Mutation; D011687:Purines / Q000378:metabolism
D011687:Purines; D000493:Allopurinol; D007041:Hypoxanthine Phosphoribosyltransferase; C030985:purine